Chemokines CCL3/MIP1α, CCL5/RANTES and CCL18/PARC are independent risk predictors of short-term mortality in patients with acute coronary syndromes

• Published in: PloS one 2012-09, Vol.7 (9), p.e45804-e45804
• Main Authors: de Jager, Saskia C A, Bongaerts, Brenda W C, Weber, Michael, Kraaijeveld, Adriaan O, Rousch, Mat, Dimmeler, Stefanie, van Dieijen-Visser, Marja P, Cleutjens, Kitty B J M, Nelemans, Patty J, van Berkel, Theo J C, Biessen, Erik A L
• Format: Article
• Language: English
• Subjects: Acute Coronary Syndrome - blood; Acute Coronary Syndrome - diagnosis; Acute Coronary Syndrome - mortality; Acute coronary syndromes; Aged; Angina pectoris; Atherosclerosis; Biology; Biomarkers; Cardiology; Cardiovascular disease; Cardiovascular diseases; CCL18 protein; CCL3 protein; Chemokine CCL3 - blood; Chemokine CCL5 - blood; Chemokines; Chemokines, CC - blood; Coronary vessels; Cytokines; Diabetes; Disorders; Epidemiology; Ethics; Female; Gangrene; Health risk assessment; Health risks; Heart attacks; Humans; Inflammation; Ischemia; Kaplan-Meier Estimate; Logistic Models; Male; Medicine; Middle Aged; Mortality; Neutrophils; Pathology; Patients; Prognosis; Proportional Hazards Models; Proteins; RANTES; Risk; ROC Curve
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0045804

Cytokines play an important role in ischemic injury and repair. However, little is known about their prognostic value in cardiovascular disease. The aim of this study was to investigate the prognostic importance of chemokines CCL3/MIP-1α, CCL5/RANTES and CCL18/PARC for the risk of future cardiovascular events in patients with acute coronary syndromes (ACS). Baseline levels of CCL3/MIP-1α, CCL5/RANTES and CCL18/PARC were determined in ACS patients from the Bad Nauheim ACS II registry (n = 609). During the following 200 days, patients were monitored for the occurrence of fatal and non-fatal cardiovascular events. Patients with CCL3/MIP1α, CCL5/RANTES and CCL18/PARC concentrations in the highest tertile were associated with an increased risk of a fatal event during follow-up (HR: 2.19, 95%CI: 1.04-4.61 for CCL3/MIP1α, HR: 3.45, 95%CI: 1.54-7.72 for CCL5/RANTES and HR: 3.14, 95%CI: 1.33-7.46 for CCL18/PARC). This risk was highest for patients with all three biomarkers concentrations in the upper tertile (HR: 2.52, 95%CI: 1.11-5.65). Together with known risk predictors of cardiovascular events, CCL3/MIP-1α, CCL5/RANTES and CCL18/PARC combined improved the c-statistics from 0.74 to 0.81 (p = 0.007). In conclusion, CCL3/MIP-1α, CCL5/RANTES and CCL18/PARC are independently associated with the risk of short-term mortality in ACS patients. Combining all three biomarkers further increased their prognostic value.